An IOL-mounted sustained bimatoprost delivery system demonstrated a reduction in IOP in two clinical trials of patients with glaucoma or ocular hypertension, according to a press release from SpyGlass Pharma.
Researchers evaluated the Bimatoprost Drug Pad-IOL System (BIM-IOL System) in first-in-human and phase 1/2 trials. The BIM-IOL System uses non-bioerodible drug pads that are attached to an IOL to deliver multiple years of the prostaglandin analog bimatoprost, according to the release.
“Non-adherence to topical IOP-lowering medicines is a key driver of glaucoma disease progression and